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include hollow structures such as the bladder, as well as vascular 
structures such as urine tubes. 
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New life requirements enforce doctors navigate one of the 
most important scientific questions faced by the cancer community 
could help improve survival rates for patients. A joint initiative of 
UNICANCER, ESMO and Cancer Research UK, the meeting on 
Molecular Analysis for Personalised therapy (MAP) will explore 
clinical interpretation of molecular tests for cancers that have spread. 
By learning more about their patients' genetic makeup, 
doctors hope to develop more effective and customised strategies for 
prevention, screening and therapy. In addition, these techniques 
strive to lower treatment side effects.  
The development of new biotechnologies has revolutionised 
the applications of personalised therapy in advanced cancer that has 
spread. 
It is now possible to perform multigene sequencing for cancer 
patients, either in clinical trials or in routine use, and the knowledge 
gained will help clinicians prescribe therapies specifically adapted 
for each individual patient's case, which could reduce overall 
treatment costs and ultimately provide better care. 
Co-founder Pr Fabrice André of the Gustave Roussy Institute 
in Villejuif, explained why the programme of this new meeting was 
so vital, helping medical oncologists translate latest clinical research 
into applicable medical treatment approaches. 
The results of genomic research have already yielded results 
for new cancer therapies. Because each person‘s sequencing may 
show a myriad of mutations, may of which may be rare or unique, 
precision cancer medicine is a highly complex process, explained 
Cofounder Pr Charles Swanton, Cancer research UK scientist based 
at the Francis Crick Institute. 
 
